Creavo Medical Technologies – Parkwalk closes investment
We are pleased to announce that the Parkwalk Opportunities Fund has made an investment in Creavo Medical Technologies, a University of Leeds Spin-out company, as part of a £13.4 million fundraising.
Brainomix joins forces with Boehringer Ingelheim to help save stroke victims
Oxford – An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.
Brainomix – International Journal of Stroke Publication
Oxford – A new clinical study was conducted by Anglia Ruskin Clinical Trials Unit reporting the performance of e-ASPECTS. In this multi-centre study, non-contrast enhanced computed tomography (NCCT) images from ischemic stroke patients were evaluated by e-ASPECTS and… Read More
Healthera – University of Cambridge Enterprise Fund III investment
We are delighted to announce that the University of Cambridge Enterprise Fund III has invested in Healthera Ltd, a provider of next-generation, pharmacy-integrated personal health management solutions, has secured seed investment from the University of Cambridge, the University of… Read More
Brainomix – Parkwalk closes follow-on investment
We have recently closed an investment in Brainomix for the Parkwalk UK Tech Fund VII and the Opportunities Fund. Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses… Read More
Micrima – University of Bristol Enterprise Fund I investment
We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Micrima. The company intends to develop and commercialise a new Breast Imaging System (MARIA) aimed at radically improving breast cancer… Read More
DefiniGEN – Parkwalk closes follow on investment
Parkwalk closes DefiniGen investment for the University of Cambridge Enterprise Fund IV and Parkwalk Funds DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human… Read More
Oxford Endovascular – Parkwalk closes University of Oxford Isis Fund investment
We are delighted to announce that the University of Oxford Isis Fund II has completed an investment in Oxford Endovascular Limited, a company developing sophisticated mesh tubes to treat patients suffering from brain aneurysms. Parkwalk invested in a £2m round alongside the… Read More
First Light Fusion – £22.7m fundraise
Parkwalk portfolio company First Light Fusion has completed a fundraising of up to £22.7 million. First Light, a spin-out from the University of Oxford, has discovered new implosion processes that can achieve the high temperatures and compression necessary… Read More
Brainomix – receives Biomedical Catalyst funding to develop clinical decision-making software for stroke patients
Oxford, UK: Brainomix Limited, a developer of automated medical imaging software for neurological and cerebrovascular disorders, has been awarded £633,553 by the Biomedical Catalyst, a joint programme run by the Medical Research Council (MRC) and Innovate UK. The… Read More
Parkwalk closes Orthox investment
We are pleased to announce that Parkwalk VI, the Opportunities EIS Fund and the University of Oxford Isis Fund II have made an investment in Orthox, a tissue regenerative orthopaedic implant company with technology spun out of Oxford University. Orthox is… Read More
Omega Diagnostics – Development Update
Omega Diagnostics Group PLC – Development Update – Visitect® CD4 and Allergy Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following development update on its infectious disease and allergy projects…. Read More
Brainomix – Positive endovascular trial uses ASPECTS
A seminal paper was published in the New England Journal of Medicine describing the results of the ESCAPE trial for endovascular treatment of stroke patients. This study shows that rapid endovascular treatment leads to significantly improved functional outcomes… Read More
Oxyntix – rebranding as First Light Fusion
First Light Fusion was spun out from the University of Oxford in July 2011, with seed capital from the IP Group plc, Parkwalk and a number of Angel investors. Until May 2014, the company was named Oxyntix Ltd…. Read More
Brainomix – wins ACES award for ICT
University of Oxford Isis Fund I and Parkwalk portfolio company Brainomix wins ACES entrepreneurship prize which rewards companies working in health and environment: BERLIN – 7 October 2014. Spin-outs from Germany, Switzerland and the UK won the ACES… Read More
Brainomix – University of Oxford Isis Fund I and Parkwalk investment
We have recently closed an investment in Brainomix for the University of Oxford Isis Fund I and Parkwalk Funds. Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses for… Read More
Oxtex – University of Oxford Isis Fund I investment
We have recently made an investment in Oxtex for the University of Oxford Isis Fund I. Oxtex has developed a surgical implant device which addresses the problem created by the lack of sufficient skin in areas requiring reconstructive surgery. Oxtex… Read More
Microsaic Systems – Signs pre-contract Commercial Agreement
Microsaic Systems Signs Pre-Contract Commercial Agreement with Leading Global Supplier of Scientific Instrumentation in Healthcare Markets 14 April 2014: Microsaic Systems plc (AIM: MSYS), the high technology company developing next generation mass spectrometry instruments, is pleased to announce… Read More
Microsaic Systems – appoints FD
Microsaic Systems PLC has appointed Andrew Darby as Finance Director, with effect from April 16. The developer of miniaturised chip-based scientific instruments said Darby is replacing Malcolm Bateman who is stepping down from the company and board after… Read More
Omega Diagnostics – Trading Update
Trading Update and Notice of Results Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that results for the year to 31 March 2014 will be in line with market expectations. Revenues… Read More
